- Home
- VSTM
VSTM
Verastem Inc.
as 10-08-2025 4:00pm EST
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | NEEDHAM |
| Market Cap: | 598.2M | IPO Year: | 2012 |
| Target Price: | $13.38 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.54 - $11.24 | Next Earning Date: | 11-05-2025 |
| Revenue: | $2,137,000 | Revenue Growth: | -78.63% |
| Revenue Growth (this year): | 88.5% | Revenue Growth (next year): | 398.66% |
Stock Insider Trading Activity of Verastem Inc. (VSTM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Calkins Daniel | VSTM | Chief Financial Officer | Sep 24 '25 | Sell | $9.23 | 25 | $230.75 | 109,838 | |
| Calkins Daniel | VSTM | Chief Financial Officer | Sep 22 '25 | Sell | $9.08 | 57 | $517.56 | 109,838 | |
| Gagnon Robert E. | VSTM | Director | Sep 16 '25 | Sell | $9.99 | 281 | $2,807.19 | 41,961 | |
| Stuglik Brian M | VSTM | Director | Sep 16 '25 | Sell | $9.99 | 587 | $5,864.13 | 101,739 | |
| Paterson Dan | VSTM | President and CEO | Sep 16 '25 | Sell | $9.99 | 390 | $3,896.10 | 442,117 |
Latest Verastem Inc. News
VSTM Breaking Stock News: Dive into VSTM Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
3 months ago
Verastem’s avutometinib combination shows 31% ORR in ovarian cancer trial
Business Wire
3 months ago
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
MT Newswires
3 months ago
RBC Cuts Price Target on Verastem to $12 From $16, Keeps Outperform, Speculative Risk
MT Newswires
3 months ago
Verastem Doses First Patient in US Study of Oral Cancer Drug VS-7375
Business Wire
3 months ago
Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors
Zacks
4 months ago
Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?
Business Wire
4 months ago
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor
Zacks
4 months ago
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
Compare VSTM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VSTM Verastem Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.